Technology
Health
Biotechnology

Momenta Pharmaceuticals

$12.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.13 (-1.05%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MNTA and other stocks, options, ETFs, and crypto commission-free!

About

Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. Read More The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.

Employees
131
Headquarters
Cambridge, Massachusetts
Founded
2001
Market Cap
1.23B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
620.82K
High Today
$12.54
Low Today
$12.22
Open Price
$12.42
Volume
108.85K
52 Week High
$32.20
52 Week Low
$9.55

Collections

Technology
Health
Biotechnology
US
North America

News

Yahoo FinanceMay 9

Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference

CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig Wheeler, President and CEO, will present at the 2019 Bank of America Merrill Lynch Healthcare Conference. The presentation is scheduled for Thursday, May 16, 2019 at 9:20 a.m. PT (12:20 p.m. ET). A webcast of the presentation will be available live on the “Invest...

7
Yahoo FinanceMay 7

See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc.

2
Seeking AlphaMay 6

Momenta Pharma: Encouraging Q1 Report, Concerns Remain

The indication of HDFN is highly intriguing given preclinical data and lack of approved therapeutics. Positive data here could lead to accelerated approval and would potentially unlock several related diseases. Heavy competition in the lucrative FcRn space, with companies such as argenx and UCB having a substantial lead, is a risk factor to consider. Shares have risen by just 28% over the past five years and lost a third of their value over the past 12 months. Shares of Momenta Pharmaceuticals (MNTA) hav...

10

Earnings

-$0.91
-$0.55
-$0.18
$0.18
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.